Abstract
TUMOUR-SPECIFIC antigens have usually been demonstrated with little knowledge of their molecular nature; for example by the residual reactivity with tumour shown by an anti-tumour serum which has been absorbed with normal tissue. Certain tumours of B lymphoid cells which secrete immunoglobulin (Ig) provide a promising situation for identification of the antigen in molecular terms1–3. Amino acid sequences in the variable (V) regions of Ig molecules determine not only antibody activity, but also the ‘idiotypic’ antigenic determinants of the molecule (for review see ref. 4). In a normal B lymphoid clone the V regions on the surface Ig of the early members are the same as those on the Ig exported by specialised protein-secreting descendants and are essentially unique to this clone5,6. The morphology and mode of Ig secretion in neoplastic cells are frozen at some stage in the range shown by their normally differentiating counterparts (Fig. 1). Tumours with cells having both surface and export Ig have provided Ig in the host serum in amounts suitable for the conventional raising of anti-V sera. These sera, by reacting specifically with the surface Ig of the corresponding tumour, demonstrated that the V regions can represent tumour-specific antigens2,3. Furthermore, Lynch et al.1 demonstrated that mice immunised so as to produce antibodies to the V regions of such a tumour (a syngeneic mouse myeloma) were thereby afforded a measure of specific protection against tumour challenge.
Similar content being viewed by others
References
Lynch, R. G., Graff, R. J., Sirisinha, S., Simms, E. S., and Eisen, H. N., Proc. natn. Acad. Sci. U.S.A., 69, 1540 (1972).
Wernet, P., Feizi, T., and Kunkel, H. G., J. exp. Med., 136, 650 (1972).
Fu, S. M., Winchester, R. J., Feizi, T., Walzer, P. D., and Kunkel, H. G., Proc. natn. Acad. Sci. U.S.A., 71, 4487 (1974).
Stevenson, G. T., in Structure and Function of Plasma Proteins, 1, (edit. by Allison, A. C.), 223–263 (Plentum, London, 1974).
Mitchison, N. A., Cold Spring Harb. Symp. quant. Biol., 32, 431 (1967).
Feizi, T., Wernet, P., Kunkel, H. G., and Douglas, S. D., Blood, 42, 753 (1973).
Pernis, B., Forni, L., and Amante, L., Ann. N.Y. Acad. Sci., 190, 420 (1971).
Shevach, E. M., Ellman, L., Davie, J. M., and Green, I., Blood, 39, 1 (1970).
Stevenson, G. T., Eady, R. P., Hough, D. W., Jurd, R. D., and Stevenson, F. K., Immunology, (in the press).
Eady, R. P., Hough, D. W., Kilshaw, P. J., and Stevenson, G. T., Immunology, 26, 549 (1974).
Stevenson, G. T., Nature, 247, 477 (1974).
Pincus, C. S., Lamm, M. E., and Nussenzweig, V., J. exp. Med., 133, 987 (1971).
Taussig, M. J., and Lachmann, P. J., Immunology, 22, 185 (1972).
Taylor, R. B., Duffus, P. H., Raff, M. C., and de Petris, S., Nature new Biol., 233, 225 (1971).
Currie, G. A., and Sime, G. C., Nature new Biol., 241, 284 (1973).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
STEVENSON, G., STEVENSON, F. Antibody to a molecularly-defined antigen confined to a tumour cell surface. Nature 254, 714–716 (1975). https://doi.org/10.1038/254714a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/254714a0
- Springer Nature Limited
This article is cited by
-
Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol
BMC Cancer (2018)
-
Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients
Bone Marrow Transplantation (2013)
-
Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures
Nature Reviews Cancer (2009)
-
Vaccination strategies in follicular lymphoma
Current Hematologic Malignancy Reports (2009)
-
Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma
Bone Marrow Transplantation (2005)